
AI Spotlight on IDYA
Company Description
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations.Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability.
The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc.for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc.IDEAYA Biosciences, Inc.
was incorporated in 2015 and is headquartered in South San Francisco, California.
Market Data
Last Price | 20.24 |
Change Percentage | -2.46% |
Open | 20.7 |
Previous Close | 20.75 |
Market Cap ( Millions) | 1772 |
Volume | 629809 |
Year High | 47.72 |
Year Low | 19.96 |
M A 50 | 23.69 |
M A 200 | 32.19 |
Financial Ratios
FCF Yield | -14.19% |
Dividend Yield | 0.00% |
ROE | -26.74% |
Debt / Equity | 1.81% |
Net Debt / EBIDTA | 20.06% |
Price To Book | 1.56 |
Price Earnings Ratio | -6.02 |
Price To FCF | -7.05 |
Price To sales | 253.11 |
EV / EBITDA | -5.25 |
News
- Feb -14 - Down -8.63% in 4 Weeks, Here's Why You Should You Buy the Dip in IDEAYA Biosciences (IDYA)
- Feb -13 - IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss
- Feb -13 - IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
- Feb -13 - IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC
- Feb -10 - Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming
- Feb -10 - All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to Buy
- Feb -10 - IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer
- Jan -31 - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Jan -27 - IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events
- Jan -12 - IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance
- Dec -29 - IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors
- Dec -27 - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Dec -17 - IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma
- Dec -16 - IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers
- Dec -11 - IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024
- Dec -10 - IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
- Dec -09 - IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor
- Dec -06 - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Dec -04 - Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash
- Dec -02 - IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Oncology-focused Precision Medicine
Expected Growth : 15.4 %
What the company do ?
IDEAYA Biosciences' Oncology-focused Precision Medicine is a personalized approach to cancer treatment, leveraging DNA sequencing and AI to match patients with targeted therapies.
Why we expect these perspectives ?
Increasing adoption of precision medicine, advancements in DNA sequencing and AI, growing demand for targeted therapies, and rising cancer incidence rates drive growth in the oncology-focused precision medicine market.
Ideaya Biosciences, Inc. Products
Product Range | What is it ? |
---|---|
Targeted Protein Degradation (TPD) Platform | A novel approach to drug discovery that utilizes small molecules to selectively degrade disease-causing proteins, offering a potential solution for previously undruggable targets. |
E3 Ligase Modulators | Small molecule modulators that selectively engage E3 ubiquitin ligases to induce protein degradation, providing a new avenue for therapeutic intervention. |
Cereblon Modulators | Small molecule modulators that selectively engage the Cereblon E3 ubiquitin ligase to induce protein degradation, offering a potential solution for hematological malignancies and other diseases. |
Degrader Conjugates | A novel class of therapeutics that combine a targeting moiety with a degrader molecule, enabling the selective degradation of disease-causing proteins in specific cell types or tissues. |
Protein Degradation Profiling Services | Comprehensive profiling services that enable the identification of optimal degrader molecules and E3 ligase targets for specific disease indications. |
IDEAYA Biosciences, Inc.'s Porter Forces
Threat Of Substitutes
IDEAYA Biosciences, Inc. has a unique portfolio of precision medicine oncology products, which reduces the threat of substitutes.
Bargaining Power Of Customers
IDEAYA Biosciences, Inc. has a diverse customer base, but some large pharmaceutical companies have significant bargaining power.
Bargaining Power Of Suppliers
IDEAYA Biosciences, Inc. has a strong supply chain management system, which reduces the bargaining power of suppliers.
Threat Of New Entrants
The biotechnology industry is highly competitive, and new entrants with innovative products can pose a significant threat to IDEAYA Biosciences, Inc.
Intensity Of Rivalry
The biotechnology industry is highly competitive, and IDEAYA Biosciences, Inc. faces intense rivalry from established players and new entrants.
Capital Structure
Value | |
---|---|
Debt Weight | 0.46% |
Debt Cost | 8.31% |
Equity Weight | 99.54% |
Equity Cost | 8.31% |
WACC | 8.31% |
Leverage | 0.46% |
IDEAYA Biosciences, Inc. : Quality Control
IDEAYA Biosciences, Inc. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
Company | Rational |
---|---|
TECH | Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, … |
INSM | Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as … |
ALNY | Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, … |
ADMA | ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. … |
BBIO | BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇

Alnylam Pharmaceuticals
A-Score
1-Year Total Return ->
🥈

ADMA Biologics
A-Score
1-Year Total Return ->
🥉

Insmed
A-Score
1-Year Total Return ->
4

Bio-Techne
A-Score
1-Year Total Return ->
5

BridgeBio Pharma
A-Score
1-Year Total Return ->
6
